The Ludwig Boltzmann Institute for Cancer Research is located in the Institute of Pharmacology, where most of the research activities are carried out. The institute is headed by Richard Moriggl, who is supported by three key researchers, namely Emilio Casanova, Lukas Kenner and Dagmar Stoiber.
The LBI-CR conducts an internationally competitive research programme focused on the analysis of core cancer pathways and utilises modern tools of mouse genetics to elucidate functional cooperativity in cancer development and progression. The LBI-CR performs its research under guidance of an international Scientific Advisory Board and in close co-operation with four research institutions and a biotech Partner. The Scientific Advisory Board and the Ludwig Boltzmann Gesellschaft regularly evaluate the scientific performance and have ranked the institute's performance highly in the past. This was based on its scientific output, support for junior researchers and its ambitious research programme.
Based on an outstanding evaluation report the LBG extended funding of the LBI-CR for a second period of seven years, which started in September 2012.